Breaking News

Sanofi US, POZEN Ink Exclusive License Agreement

To commercialize PA8140/PA32540 Tablets in the U.S.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sanofi US and Pozen, Inc. have signed an exclusive license agreement to commercialize Pozen’s investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor (PPI), and enteric-coated aspirin in a single tablet, PA8140 and PA32540. Sanofi will have exclusive rights to commercialize all PA combinations that contain 325 mg or less of enteric-coated aspirin in the U.S. and Pozen will receive an upfront payment of $15 million and will be eligible ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters